Insider buying last 90 days
No open-market insider purchases were filed for AXSM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Axsome Therapeutics this week centered on third-quarter results and analyst reaction. Revenue grew 52% year-over-year to $260 million, with AUVELITY contributing $208 million in net sales and SUNOSI adding $48.2 million, while EPS of $-0.25 beat estimates. Following the report, UBS adjusted its price target to $239 from $256 while maintaining a Buy rating, and management participated in the Guggenheim Healthcare Innovation Conference and other investor events during the month.
Shares closed at $133.96, up 1.2%, but remain below both the 50-day average of $176.31 and the 200-day average of $197.88, with the 50-day sitting below the 200-day. Over the past month the stock has returned -20.4%, and over six months -38.1%. The GekkoIndex reads 69.9, placing the stock in the Accumulation zone, while the price sits 36.7% below the Gekko Fair Value of $211.58.
The next earnings date falls on 22 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality data from this point in the calendar shows the next 20 trading days averaging +7.2% over 5 years, with gains in 4 of those years. Analyst sentiment remains broadly positive, with 18 of 19 firms rating the stock Buy and a consensus target of $271.05.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Axsome Therapeutics scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
Below 50 and 200-day
Close $141.69 is below the 50-day ($171.45) and 200-day ($197.05) averages, and the 50-day is below the 200-day.
See the chart62.6, Accumulation
Reading 62.6 is in the Accumulation zone.
See the GekkoIndex31.5% below
Price is 31.5% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 99 days
Next report Feb 22, 2027, 99 days away — outside a typical 20-trading-day hold.
See earnings+8.9% on average
From this point in the calendar, the next 20 trading days averaged +8.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Axsome Therapeutics closed at $141.69 on Nov 13, 2026, +0.6% over the past year, inside a 52-week range of $123.00 to $260.19.
Use the left and right arrow keys to read daily values.
Put AXSM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Axsome Therapeutics works on developing treatments for disorders of the central nervous system, focused on patients in the United States. The company is best known for its pipeline of investigational drugs targeting conditions such as depression, Alzheimer's-related agitation, migraine, narcolepsy and fibromyalgia, with several candidates moving through Phase III trials at various stages of study.
Its work centers on advancing these compounds through clinical development rather than selling approved products, with each candidate aimed at a specific CNS condition. Axsome Therapeutics also collaborates with Duke University to study one of its compounds for use in smoking cessation, extending the potential applications of its research beyond the primary conditions it targets.
The company was founded in 2012 and is headquartered in New York, New York. Its shares trade on the NASDAQ under the ticker AXSM.
Axsome Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.6, in the Accumulation zone, down 9.3 points over five sessions.
Down 9.3 points over five sessions, from the Buying zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 42 | −2.1% | +0.6% | ||
| Accumulation (current zone) | 187 | +0.4% | +3.2% | ||
| Neutral | 416 | +0.8% | +2.3% | ||
| Distribution | 53 | +0.2% | −1.0% | ||
| Selling | 4 | Too few readings yet | |||
Average AXSM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Axsome Therapeutics trades 31.5% below Gekko Fair Value of $206.85, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Axsome Therapeutics shares are worth, recalculated every trading day.
$206.85
Gekko Fair Value, Nov 14, 2026
31.5% Undervalued
At the end of Aug 2026 the price was 25.0% below the estimate.
No open-market insider purchases were filed for Axsome Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for AXSM in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in AXSM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold AXSM.
Axsome Therapeutics reports on Feb 22, 2027, before the open (99 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 22, 2027
Expected before the open, 99 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | −$0.25 est −$0.63 | $259.7M est $249.2M | −3.3% |
| Aug 10, 2026 | −$0.99 est −$0.89 | $216.4M est $221.1M | +1.4% |
| May 4, 2026 | −$1.26 est −$0.86 | $189.4M est $190.9M | +8.0% |
| Feb 23, 2026 | −$0.56 est −$0.73 | $194.7M est $193.4M | −7.5% |
| Nov 3, 2025 | −$0.94 est −$0.82 | $171.0M est $191.3M | 0.0% |
| Aug 4, 2025 | −$0.92 est −$1.00 | $150.0M est $140.0M | +0.6% |
| May 5, 2025 | −$0.80 est −$1.26 | $121.5M est $140.4M | 0.0% |
| Feb 18, 2025 | −$0.96 est −$1.00 | $118.8M est $119.5M | −3.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Axsome Therapeutics is $265.86, +87.6% from the last close, from 19 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 19 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $223 | +57.4% |
| Nov 9 | H.C. Wainwright | $290 | +104.7% |
| Nov 4 | Mizuho Securities | $272 | +92.0% |
| Nov 3 | UBS | $239 | +68.7% |
| Nov 3 | Robert W. Baird | $220 | +55.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Axsome Therapeutics averaged +8.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.3% | 2 of 5 |
| Next 10 trading days | +6.8% | 4 of 5 |
| Next 15 trading days | +8.6% | 4 of 5 |
| Next 20 trading days | +8.9% | 3 of 5 |
| Next 30 trading days | +10.3% | 3 of 5 |
For scale, AXSM’s typical 20-trading-day move in either direction is about 9.7%.
Axsome Therapeutics’s market cap is $7.45B and revenue of $865.3M over the last twelve months.
Coverage of Axsome Therapeutics this week reads neutral: 2 positive, 0 neutral and 2 negative headlines.
Axsome Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Axsome Therapeutics’s market cap is $7.45B at the Nov 13, 2026 close of $141.69, with 52.60M shares outstanding.
The consensus analyst 12-month price target for Axsome Therapeutics is $265.86, +87.6% from the last close. Of the 19 firms that rated the stock in the last 90 days, 18 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Axsome Therapeutics is undervalued: the Nov 13, 2026 close of $141.69 is 31.5% below Gekko Fair Value of $206.85. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Axsome Therapeutics is expected to report on Feb 22, 2027, before the market opens (99 days away). Analysts expect earnings of −$0.05 per share on revenue of $284.0M. Axsome Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 3% on average across the report.
Axsome Therapeutics’s 52-week high is $260.19 and its 52-week low is $123.00; it closed at $141.69 on Nov 13, 2026, +0.6% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.